Full Press Release Details
Phase 3 NORA data of ZEJULA (niraparib) demonstrate significant PFS benefit in Chinese women with platinum-sensitive recurrent ovarian cancer.
ZLAB
Phase 3 NORA data of ZEJULA (niraparib) demonstrate significant PFS benefit in Chinese women with platinum-sensitive recurrent ovarian cancer
Key Takeaway: Phase 3 NORA data of ZEJULA (niraparib) demonstrate significant PFS benefit in Chinese women with platinum-sensitive recurrent ovarian cancer
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Cash runway
~28 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Small-cell Lung Cancer